Granted Patent
B2
US 12,428,374 · App. 18/534,253 · Granted Sep 30, 2025
Malassezin and analogs thereof as skin brightening agents
Assignee:
VERSICOLOR TECHNOLOGIES, LLC
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to compounds, compositions, and methods for brightening skin. The compounds, compositions, and methods of the present invention generally involve compounds produced by a Malassezia yeast, and chemical analogs thereof. In addition to skin brightening applications, the compounds, compositions, and methods of the present invention may be used to modulate melanocyte activity, induce melanocyte apoptosis, agonize an arylhydrocarbon receptor (AhR), improve hyperpigmentation caused by a hyperpigmentation disorder, and modulate melanin production, melanosome biogenesis, and melanosome transfer.
Claims (23)
1. A method for brightening skin in a subject comprising:
contacting the subject with a compound having the structure of formula (II):
wherein:
R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from the group consisting of hydrogen and methyl;
or a crystalline form, hydrate, or cosmetically or pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the compound is selected from the group consisting of:
3. The method of claim 1 , wherein the compound is:
4. A method for brightening skin in a subject comprising:
contacting the subject with a composition comprising a compound having the structure of formula (II):
wherein:
R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , Rio, and R 11 are hydrogen;
or cosmetically or pharmaceutically acceptable salt thereof, wherein:
the composition further comprises one or more of vitamin A, vitamin C, vitamin E, a polyol, and an organic ester.
5. The method of claim 4 , wherein the composition comprises vitamin A.
6. The method of claim 4 , wherein the composition comprises vitamin C.
7. The method of claim 4 , wherein the composition comprises vitamin E.
8. The method of claim 4 , wherein the composition comprises a polyol.
9. The method of claim 8 , wherein the polyol is glycerol.
10. The method of claim 4 , wherein the composition comprises an organic ester.
11. The method of claim 10 , wherein the composition comprises ethyl oleate.
12. The method of claim 10 , wherein the composition comprises a triglyceride.
13. The method of claim 4 , wherein the composition is a topical or transdermal composition.
14. The method of claim 13 , wherein the composition is an ointment, paste, cream, lotion, gel, solution, emulsion or suspension.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 3, 2024
From: EINZIGER, MICHAEL; SIMPSON, ANN MARIE
To: VERSICOLOR TECHNOLOGIES, LLC
Reel/Frame 069462/0541 →
Continuity (5)
Provisional Application
62306468
· Mar 10, 2016
References Cited (79)
US 7855310B2
· Herrman et al.
· 2010
[cited by applicant]
US 9969686B2
· Foundation
· 2018
[cited by applicant]
US 20070258921A1
· Dalk
· 2007
[cited by applicant]
US 20100324109A1
· Saurat
· 2010
[cited by applicant]
JP 2007297387A
· 2007
[cited by applicant]
JP 2009536933A
· 2009
[cited by applicant]
JP 2010037251A
· 2010
[cited by applicant]
WO 2002068389A2
· 2002
[cited by applicant]
WO 2009093207A1
· 2009
[cited by applicant]
AU First Examination Report for AU Application No. 2021232745 dated Dec. 5, 2022 (11 pages).
[cited by applicant]
BR Office Action for BR Application No. 112018068293-4 dated Oct. 1, 2021 (4 pages).
[cited by applicant]
English Translation of BR Office Action for BR Application No. 112018068293-4 dated Oct. 1, 2021 (4 pages).
[cited by applicant]
Berridge et al., “The Biochemical and Cellular Basis of Cell Proliferation Assays that Use Tetrazolium Salts”, Biochemica, vol. 4, pp. 14-19 1996, May 7, 2025.
[cited by applicant]
Black et al., “Athymic Nude Mice and Human Skin Grafting”, Maibach et al. (eds), Model Dermatology, vol. 1, pp. 228-239 1985, May 7, 2025.
[cited by applicant]
CA Office Action for CA Application No. 3017352 dated Apr. 28, 28, 2020 (11 pages).
[cited by applicant]
CA Office Action for CA Application No. 3017352 dated May 5, 2022 (3 pages).
[cited by applicant]
CA Office Action for CA Application No. 3017352 dated Oct. 26, 2020 (3 pages).
[cited by applicant]
Coston et al., “Optimized in Vitro Pigmentation Screening Assay Using a Reconstructed Three Dimensional Human Skin Model”, Rom. J. Biochem., vol. 50, No. 1, 2013, pp. 15-27.
[cited by applicant]
“Dimethyl Sulfoxide”, Handbook of Pharmaceutical Excipients, Sixth Edition, Ed. Rowe R et al., Pharmaceutical Press and the American Pharmacists Association, 2009, pp. 238-240 (3 pages).
[cited by applicant]
Donato et al., “A Microassay for Measuring Cylochrome P450IA1 and P450IIB1 Activities in Intact Human and Rat Hepatocytes Cultured on 96-Well Plates”, Anal Biochem, vol. 213, No. 1, 1993, pp. 29-33.
[cited by applicant]
Elmore, Susan, “Apoptosis: A Review of Programmed Cell Death”, Toxicologic Pathology, vol. 35, No. 4, 2007, pp. 495-516.
[cited by applicant]
EP Office Action for EP Application No. 17711992.2 dated Nov. 25, 2019 (6 pages).
[cited by applicant]
EP Office Action for EP Application No. 17711992.2 dated Jan. 3, 2022 (5 pages).
[cited by applicant]
European Patent Office (EPO) Communication, European Patent Application No. 17711992.2, Oct. 28, 2020.
[cited by applicant]
Examination Report for EP Application No. 17711992.2 dated Jun. 23, 2023 (4 pages).
[cited by applicant]
Examination Report for IN Application No. 201817037406 dated Nov. 26, 2019 (7 pages).
[cited by applicant]
Examination Report for IN Application No. 202118021156 dated Feb. 8, 2022 (8 pages).
[cited by applicant]
Examination Report for PH Application No. 1/2018/501926 dated Oct. 1, 2020 (4 pages).
[cited by applicant]
Examination Report for PH Application No. 1/2018/501926 dated Aug. 13, 2021 (4 pages).
[cited by applicant]
Examination Report No. 1 for AU Application No. 2017229970 dated Sep. 16, 2020 (8 pages).
[cited by applicant]
Examination Report No. 2 for AU Application No. 2017229970 dated Sep. 14, 2021 (5 pages).
[cited by applicant]
Examination Report No. 2 for AU Application No. 2021232745 dated Dec. 4, 2023 (3 pages).
[cited by applicant]
Fitzpatrick et al., “The Validity and Practicality of Sun-Reactive Skin Types I Through VI”, Arch Dermatol., vol. 124, No. 6, pp. 869-871 1988, May 7, 2025.
[cited by applicant]
Gaitanis et al. , “Skin Diseases Associated with Malassezia Yeasts: Facts and Controversies”, Clinics in Dermatology, vol. 31, 2013, pp. 455-463.
[cited by applicant]
Gueho et al., “The Genus Malassezia with Description of Four New Species”, Antonie Van Leeuwenhoek, vol. 59, 1996, pp. 337-355.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2017/021843 dated Apr. 21, 2017.
[cited by applicant]
IL Office Action for IL Application No. 287141 dated Nov. 2, 2022 (4 pages).
[cited by applicant]
Jux, B. et al., “The Aryl Hydrocarbon Receptor Mediates UVB Radiation-Induced Skin Tanning,” Journal of Investigative Dermatology, vol. 131, 2011, pp. 203-210.
[cited by applicant]
Karchner et al., “Identification and Functional Characterization of Two Highly Divergent Aryl Hydrocarbon Receptors (AHR1 and AHR2) in the Teleost Fundulus Heteroclitus”, The Journal of Biological Chemistry, vol. 274, N…
[cited by applicant]
Kramer et al., “Malassezin, A Novel Agonist of the aryl hydrocarbon receptor from the yeast Malassezia furfur, induces apoptosis in primary human melanocytes”, ChemBioChem, vol. 6, No. 5, 2005, pp. 860-865.
[cited by applicant]
Lee et al., “Comparison of Gene Expression Profiles Between Keratinocytes, Melanocytes and Fibroblasts”, Ann. Dermatology, vol. 25, No. 1, 2013, pp. 36-45.
[cited by applicant]
Lodén, Marie, “Role of Topical Emollients and Moisturizers in the Treatment of Dry Skin Barrier Disorders”, Am J Clin Dermatol, vol. 4, No. 11, 2003, pp. 771-788.
[cited by applicant]
Luecke et al The aryl hydrocarbon receptor (AHR), a novel regulator of human melanogenesis, Pigment Cell Melanoma Res., vol. 23, 2010, pp. 828-833.
[cited by applicant]
Lynde, C.W., “Moisturizers: What They Are And How they Work”, STL, vol. 6, No. 13, Dec. 1, 2001.
[cited by applicant]
Magiatis, P. et al.(2013). “Malassezia Yeasts Produce a Collection of Exceptionally Potent Activators of Ah (Dioxin) Receptor Detected in Diseased Human Skin,” Journal of Investigative Dermatology, vol. 133, 2013, pp. 2…
[cited by applicant]
Manning et al., “Maintenance of Skin Xenografts of Widely Divergent Phylogenetic Origin on Congenitally Athymic (Nude) Mice”, J Exp Med, vol. 138, 1973, pp. 488-494.
[cited by applicant]
Mexican Institute of Industrial Property (IMPI) Communication for MX Application No. MX/A/2018/010962 dated Mar. 12, 2021 (Original and English-language translation).
[cited by applicant]
Nazzaro-Porro et al., “Identification of Tyrosinase Inhibitors in Cultures of Pityrosporum”, The Journal of Investigative Dermatology, vol. 71, 1978, pp. 205-208.
[cited by applicant]
Noakes, Rowland, “The Aryl Hydrocarbon Receptor: A Review of Its Role in the Physiology and Pathology of the Integument and Its Relationship to the Tryptophan Metabolism”, Journal of Tryptophan Research, vol. 8, 2015, p…
[cited by applicant]
Notice of Acceptance for AU Application No. 2017229970 dated Sep. 22, 2021 (3 pages).
[cited by applicant]
Notice of Allowance for KR Application No. 10-2018-7029239 dated Apr. 22, 2021 (3 pages).
[cited by applicant]
Notice of Reasons for Refusal for JP Application No. 2020-131521 dated May 2, 2022 (8 pages).
[cited by applicant]
Otulakowski et al, “Use of a Human Skin-Grafted Nude Mouse Model for the Evaluation of Topical Retinoic Acid Treatment”, J Invest Dermatol, vol. 102, 1994, pp. 515-518.
[cited by applicant]
Park et al., “Inhibitory Effect of 2-methyl-naphtho [1,2,3-de] quinoline-8-one on melanosome transport and skin pigmentation”, Sci Rep Jul, vol. 29189, No. 6, 2016, DOI: 10.1038/srep29189.
[cited by applicant]
Plenat et al., “Host-Donor Interactions in Healing of Human Split-Thickness Skin Grafts Onto Nude Mice: In Situ Hybridization, Immunohistochemical and Histochemical Studies”, Transplantation, vol. 53, 1992, pp. 1002-101…
[cited by applicant]
Reed et al., “Long-Term Maintenance of Normal Human Skin on Congenitally Athymic (Nude) Mice”, Proc Soc Exp Bio Med, vol. 143, 1973, pp. 350-353.
[cited by applicant]
Scott et al., “The Permeability of Grafted Human Transplant Skin in Athymic Mice”, J Pharm Pharmacol, vol. 40, 1968, pp. 128-129.
[cited by applicant]
Song et al., “A Ligand for Aryl Hydrocarbon Receptor Isolated From Lung”, Proceedings of the National Academy of Sciences, vol. 99, No. 23, 2002, pp. 14694-14699.
[cited by applicant]
Taylor et al., “The Taylor Hyperpigmentation Scale: a new visual assessment tool for the evaluation of skin color and pigmentation”, Cutis, vol. 76, No. 4, 2005, pp. 270-274.
[cited by applicant]
Tholander et al., “Synthesis of 6-Formylindolo [3,2-b] carbazole, an Extremely Potent Ligand for the Aryl Hydrogen (Ah) Receptor”, Tetrahedron Letters, vol. 39, 1998, pp. 1619-1622.
[cited by applicant]
Tholander et al., “Syntheses of 6, 12-Disubstituted 5,11-Dihydroindolo [3,2-b] carbazoles, Including 5, 11-Dihydroindolo [3,2-b] carbazole-6, 12-dicarbaldehyde, an Extremely Efficient Ligand for the TCDD (Ah) Receptor”,…
[cited by applicant]
Tholander et al., “Syntheses of 6-Substituted Indolo [3,2-b] carbazoles, Including 6-Formylindolo [3,2-b] carbazole, an Extremely Efficient Ligand for the TCDD (Ah) Receptor”, Tetrahedron, vol. 55, 1999, pp. 6243-6260.
[cited by applicant]
Waller et al., “Three-Dimensional Quantitative Structure-Activity Relationships Dioxins and Dioxin-like Compounds: Model Validation and Ah Receptor Characterization”, Chem. Res. Toxicol., vol. 8, 1995, pp. 847-858.
[cited by applicant]
Wang et al., “Sress-Induced RNASET2 Overexpression Mediates Melanocyte Apoptosis Via The TRAF2 Pathway In Vitro”, Cell Death and Disease, vol. 5, 2014, pp. e1022.
[cited by applicant]
Wasmeier et al., “Melanosomes at a Glance”, Journal of Cell Science, vol. 121, 2008, pp. 3995-3999.
[cited by applicant]
Whyte et al., “Ethoxyresorufin-O-deethylase (EROD) Activity in Fish as a Biomarker of Chemical Exposure”, Critical Reviews in Toxicology, vol. 30, No. 4, 2000, pp. 347-570.
[cited by applicant]
Wille et al., “Malassezian—A Novel Agonist of the Arylhydrocarbon Receptor from the Yeast Malassezia Furfur”, Bioorganic & Medicinal Chemistry, vol. 9, 2001, pp. 955-960.
[cited by applicant]
Winston-McPherson et al., “Synthesis and Biological Evaluation of 2,3′-diindolylmethanes as Agonists of Aryl Hydrocarbon Receptor”, Bioorganic & Medicinal Chemistry Letters, vol. 24, 2014, pp. 4023-4025.
[cited by applicant]
Written Opinion for SG Application No. 11201807773Q dated Apr. 12, 2021 (6 pages).
[cited by applicant]
Yamaguchi et al., “Melanocytes and Their Diseases”, Cold Spring Harb Perspect Med, vol. 4, No. a017046, 2014, DOI: 10.1101/cshperspect.a017046.
[cited by applicant]
Zonios et al., “Skin Melanin, Hemoglobin, and Light Scattering Properties can be Quantitatively Assessed in Vivo Using Diffuse Reflectance Spectroscopy”, J Invest Dermatol, vol. 117, 2001, pp. 1452-1457.
[cited by applicant]